NervGen Pharma Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van NervGen Pharma is gedaald met een gemiddeld jaarlijks tempo van -22.9%, terwijl de winst van de sector Pharmaceuticals jaarlijks groeide met 46%.

Belangrijke informatie

-22.9%

Groei van de winst

-2.5%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	23.1%
Inkomstengroei	n/a
Rendement op eigen vermogen	-184.8%
Nettomarge	n/a
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Oct 23

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Jun 11

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

Feb 02

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Nov 23

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Jun 29

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 16

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 08

Opbrengsten en kosten

Hoe NervGen Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

TSXV:NGEN Opbrengsten, kosten en inkomsten (CAD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	-23	9	10
31 Mar 24	-20	10	8
31 Dec 23	-22	10	8
30 Sep 23	-20	9	10
30 Jun 23	-19	8	13
31 Mar 23	-20	7	16
31 Dec 22	-21	6	17
30 Sep 22	-19	6	14
30 Jun 22	-19	6	13
31 Mar 22	-15	6	10
31 Dec 21	-13	6	7
30 Sep 21	-13	5	8
30 Jun 21	-12	5	6
31 Mar 21	-12	5	6
31 Dec 20	-11	5	6
30 Sep 20	-10	5	5
30 Jun 20	-10	4	6
31 Mar 20	-9	4	5
31 Dec 19	-10	3	6
30 Sep 19	-8	3	5
30 Jun 19	-6	2	4
31 Mar 19	-4	1	3
31 Dec 18	-1	1	1
30 Sep 18	-1	0	0
30 Jun 18	0	0	0

Kwaliteitswinsten: NGEN is momenteel verliesgevend.

Groeiende winstmarge: NGEN is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: NGEN is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 22.9% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van NGEN over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: NGEN is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( -40.8% ).

Rendement op eigen vermogen

Hoge ROE: NGEN heeft een negatief Return on Equity ( -184.82% ), omdat het momenteel verliesgevend is.

NervGen Pharma Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Insufficient new directors

NervGen Pharma Corp. Appoints Neil Klompas to Board of Directors

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Insufficient new directors

NervGen Pharma Corp. Approves Board and Audit Committee Elections

New minor risk - Market cap size

New major risk - Negative shareholders equity

CEO, President & Director recently bought CA$338k worth of stock

NervGen Pharma Corp., Annual General Meeting, Jun 04, 2024

New minor risk - Market cap size

Independent Director exercised options to buy CA$272k worth of stock.

Co-Founder & Independent Director exercised options to buy CA$347k worth of stock.

New minor risk - Share price stability

Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?

NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury

Nervgen Pharma Appoints John Ruffolo to Board of Directors

NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation

Price target increased by 8.6% to CA$6.00

Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?

NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

High number of new and inexperienced directors

Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291

NervGen Pharma Corp. Receives Up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury

NervGen Pharma Corp. Announces Executive Changes

NervGen Pharma Corp., Annual General Meeting, Sep 28, 2022

NervGen Pharma Corp. announced that it has received $15.225 million in funding from PFP Biosciences Holdings

NervGen Pharma Corp. Appoints Adam Rogers to its Board of Directors

NervGen Pharma Corp. announced that it expects to receive $15.225 million in funding

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Nervgen Pharma Corp. Receives Approval from the Safety Review Committee to Advance to the Third and Highest Dose Cohort in the Multiple Ascending Dose Portion of Phase 1 Clinical Trial of the Company's Proprietary Lead Compound, NVG-291

President exercised options to buy CA$112k worth of stock.

Independent Director exercised options to buy CA$224k worth of stock.

Less than half of directors are independent

NervGen Pharma Corp. Announces Executive Changes

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

High number of new directors

NervGen Pharma Corp. announced that it has received CAD 2.321075 million in funding

NervGen Pharma Corp. announced that it has received CAD 2.343036 million in funding

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 5.0375 million.

NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

NervGen Pharma Corp. Provides Regulatory Update on Development Program for NVG-291

Nervgen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program

New 90-day high: CA$2.41

New 90-day high: CA$1.90

New 90-day high: CA$1.85

NervGen Pharma Corp. Appoints Dr. Randall Kaye to the Company's Board of Directors

NervGen Pharma Corp. Provides an Update on NVG-291

New 90-day low: CA$1.43

New 90-day low - CA$1.52

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 6.45 million.

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden